For research and educational purposes only. Not medical advice.
Centrophenoxine Reference
Educational, not medical advice reference for Centrophenoxine: Nootropic, Longevity; regulatory status, evidence posture, source review, and schedule notes.…
Reference summary
Older European clinical literature on cerebral metabolism and lipofuscin reduction in elderly cognitive-impairment populations.
- Categories
- Nootropic, Longevity
- Aliases
- Lucidril, Meclofenoxate
- Evidence posture
- human — Not FDA-approved in the US. Older non-US approval. Trial methodology is dated; community longevity framing outruns modern evidence.
- Regulatory status
- No FDA-approved centrophenoxine drug label. Approved in Hungary and a few non-US markets for cognitive impairment and lipofuscin clearance.
- Content review status
- research reference